U.S. Markets closed

Mylan N.V. (MYL)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
30.72+0.16 (+0.52%)
At close: 4:00PM EDT
People also watch
TEVAPRGOAGNBIIBENDP

Mylan N.V.

Building 4
Trident Place
Hatfield AL10 9UL
United Kingdom
44 17 0785 3000
http://www.mylan.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees35,000

Key Executives

NameTitlePayExercisedAge
Ms. Heather BreschCEO & Exec. Director4.27MN/A48
Mr. Rajiv MalikPres & Exec. Director2.85MN/A56
Mr. Kenneth S. ParksChief Financial Officer1.44MN/A54
Mr. Anthony MauroChief Commercial Officer1.87MN/A44
Mr. Paul B. CampbellChief Accounting Officer, Sr. VP and Corp. ControllerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; antiretroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures; and Dymista, which is used for the treatment of seasonal allergic rhinitis. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, and group purchasing organizations; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hatfield, the United Kingdom.

Corporate Governance

Mylan N.V.’s ISS Governance QualityScore as of August 1, 2017 is 10. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.